Lucius Partners Announces the Addition of Centaur Bio, Inc. to the Portfolio

Centaur’s precision medicine technology, licensed from Duke University School of Medicine, transports difficult to deliver agents across the blood brain barrier. Multiple Oncology and CNS indications; first IND expected to be open in Q2 of 2023. NEW YORK, Feb. 6, 2023 /PRNewswire/ –…

Click here to view original post